Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.70 |
| ▸ | THRA | P10827 | 18/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24632157 | 0.94 | THRB (0.68) | THRBTHRARAB9A | |
| SCHEMBL21286578 | 0.93 | THRB (0.62) | THRBTHRARAB9A | |
| SCHEMBL21286594 | 0.92 | THRB (0.70) | THRBTHRARAB9A | |
| SCHEMBL21286552 | 0.91 | THRB (0.72) | THRBTHRARAB9A | |
| SCHEMBL21286638 | 0.91 | THRB (0.72) | THRBTHRARAB9A | |
| SCHEMBL19859431 | 0.89 | THRB (0.70) | THRBTHRA | |
| SCHEMBL21286550 | 0.89 | THRB (0.74) | THRBTHRARAB9A | |
| SCHEMBL21286522 | 0.88 | THRA (0.68) | THRBTHRA | |
| SCHEMBL21286586 | 0.88 | THRB (0.70) | THRBTHRA | |
| SCHEMBL21286579 | 0.88 | THRB (0.70) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578032-B2 | Derivatives of sobetirome | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2022236133-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | AUTOBAHN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20210002208-A1 | DERIVATIVES OF SOBETIROME | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019160980-A1 | DERIVATIVES OF SOBETIROME | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002208-A1 | DERIVATIVES OF SOBETIROME | SLC6A3, TPH1, SLC6A2 | THRB 149/4885THRA 213/4885RAB9A 3848/4885 |
| US-11578032-B2 | Derivatives of sobetirome | SLC6A3, TPH1, SLC6A2 | THRB 149/4885THRA 213/4885RAB9A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.